Rep. Wasserman Schultz Introduces Bipartisan PKD Cures Act to Tackle $3 Billion Kidney Disease Crisis
The PKD Cures Act is currently in the House Committee on Energy and Commerce, where it has been since June 3, 2026. The bill is waiting for the committee to review it, but no further action has taken place. Most bills do not move past this stage, and there is no sign of progress for this proposal.
This bill has support from both Democrats and Republicans, which helps its chances. However, many bills that focus on specific diseases face a long road to becoming law because of budget limits.
Scores run from -100 (strongly harmful) to +100 (strongly beneficial) for each group, combining impact, certainty, scope, and duration ratings of 1-5. How impact scoring works
PKD-related kidney failure costs Medicare roughly $3 billion per year. If the expanded research leads to treatments that prevent or delay kidney failure, Medicare could see significant long-term savings by reducing the number of patients needing expensive dialysis and transplants. However, this outcome depends on successful research breakthroughs, which are inherently uncertain.
“End-stage renal disease and kidney failure attributable to cystic kidney diseases, like PKD, cost Medicare an estimated $3,000,000,000 annually.”
Referred to the House Committee on Energy and Commerce.
Introduced in House
The bill was officially filed and given a number. It now enters the legislative queue.
No votes or related bills recorded for this bill yet.
Document Type
Congressional Bill
Official Title
PKD Cures Act
Analysis generated by AI. Always verify with official sources.